PRICE TO CASH-FLOW

Price to Cash-Flow of Medy-Tox




A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Price to Cash-Flow analysis of Medy-Tox

04-30-2020

 Price KRW  115,600.00
 Cahs-flow per share KRW  5,694.58
 Capitalization (mn) KRW  486,131
 Free Cash-flow (mn) KRW  34,167
 P/CF ratio 20.30
 Medy-Tox dividend
 Medy-Tox Price to book Value
 Medy-Tox Price to earnings
 Medy-Tox Return on Equity

Medy-Tox is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Medy-Tox headquarters are in Korea, where the firm is listed.

At the time of this analysis, Medy-Tox stocks were trading at a price of 115,600.00 KRW after collapsing their price by -78.70% last twelve months.

According to the chart displayed below, Medy-Tox Price to Cash-flow Ratio is 20.30, bigger than the amount offered by both firms from Korea and fromPharmaceuticals and Biotechnology sector. This high P/CF might be a sign of a overvalued company, but also a healthy sign because the market expects growing cash-inflows (or a reduction in cash-outflows) in the future. Therefore, it is necessary to study Medy-Tox financial situation to reach a conclussion.

Finally, you could draw a comparisson Medy-Tox P/CF with other Pharmaceuticals and Biotechnology companies or firms from Korea.

Medy-Tox price to earnings

Next companies

Mega Financial Hldg. Taiwan. Financials.

Megacable Holdings S. Mexico. Consumer Services.

Megaworld. Philippines. Financials.

Meggitt. UK. Industrials.

Megmilk Snow Brand. Japan. Consumer Goods.

Meiji Holdings. Japan. Consumer Goods.

Previous companies

Medtronic plc. USA. Health Care.

Medipal Holdings. Japan. Health Care.

Banca Mediolanum. Italy. Financials.

Mediobanca. Italy. Financials.

Medibank Private. Australia. Financials.

MediaTek. Taiwan. Technology.

All rights reserved

 information advertisement legal

Dividends Ranking | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.